Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2026)

Recursion Pharmaceuticals has reported Cash from Operations for 7 years, with the latest figure at 81101000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 38.54% year-over-year to 81101000.0; the trailing twelve-month figure through Mar 2026 stood at 320952000.0 (up 17.46% YoY), and the FY2025 full-year result was 371808000.0, down 3.52% from the prior year.
• Cash from Operations for Q1 2026 stood at 81101000.0, down from 46073000.0 in the prior quarter.
• The five-year high for Cash from Operations was 77388000.0 in Q1 2022, with the low at 131957000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 69611000.0 across 5 years, with a median of 73316000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations jumped 351.63% — and 2023, when it plunged 194.74%.
• Recursion Pharmaceuticals' Cash from Operations stood at 44748000.0 in 2022, then tumbled by 65.54% to 74077000.0 in 2023, then slumped by 55.82% to 115430000.0 in 2024, then surged by 60.09% to 46073000.0 in 2025, then plunged by 76.03% to 81101000.0 in 2026.
• The last three Cash from Operations figures came in at 81101000.0 (Q1 2026), 46073000.0 (Q4 2025), and 117360000.0 (Q3 2025), per Business Quant data.